

CURRENT CRU PROJECTS

IRBNet#	PRINCIPAL INVESTIGATORS	PROTOCOL DESCRIPTION	SPONSORS	RESEARCH TEAM Contacts
DEPARTMENT OF NEUROLOGY				
700301	Burt Jubelt, MD	A Multicenter, prospective, randomized, placebo-controlled, double-blind, parallel-group to assess the Efficacy & Safety of Immune Globulin Intravenous (Human) Flebofamma 5% Diff in pts w/ post-polio syndrome.	Instituto Grifols, S.A.	Muhammad Igbal 315-464-1814
775990	Burt Jubelt, MD	A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409)	Sanofi	Muhammad Igbal 315-464-1814
844751	Dragos Mihaila, MD	A Randomized, Double-Blind, Placebo-Controlled Trial of Urate-Elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's Disease	NINDS	Jacob Pusey 315-464-9767
981230	Debra Bradshaw, MD	A Phase 3, Open Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)	Cytokinetics	Jacob Pusey 315-464-9767
984756	Amy Sanders, MD	A phase 2A Multicenter, Randomized, Double Blind, Parallel Group, 26 Week, Placebo-Controlled Study of 50mg and 100 mg SUVN-502 in Subjects with Moderate Alzheimer's Disease Currently Treated with Donepezil Hydrochloride and Memantine Hydrochloride	Suven Life Sciences, Ltd.	Muhammad Igbal 315-464-1814
996635	Amy Sanders, MD	Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-ranging study of Piromelatine in Patients with Mild Dementia due to Alzheimer's Disease	Neurim Pharmaceuticals	Lena Deb 315-464-9756
1015330	Burt Jubelt, MD	A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate	Alkermes, Inc.	Muhammad Igbal 315-464-1814
1032689	Burt Jubelt, MD	A Phase 3 Open-Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 In Adults with Relapsing Remitting Multiple Sclerosis	Alkermes, Inc.	Muhammad Igbal 315-464-1814
1097143	Debra Bradshaw, MD	A Phase 2 Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled to Evaluate the Efficacy, Safety, and Tolerability of CK-2127107 in Patients with ALS	Cytokinetics	Jacob Pusey 315-464-9767
1163178	Robert Beach, MD, PhD, FAAN	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 study exploring the	Biogen	Muhammad Igbal

CURRENT CRU PROJECTS

		efficacy, safety, and tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult subjects with Drug-resistant Focal Epilepsy.		315-464-1814
1178214	Sulada Kanchana, MD, PhD	A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 once daily compared to its individual components in subjects with Early Parkinson's to a Calibration Arm of Pramipexole E	Pharma Two B Ltd	Jacob Pusey 315-464-9767